Dawna Franklin
Women's Health · Birmingham, ALNPI 1174587554
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,700 of the $4,760 with a category attached, or 77.7%. 32 manufacturers reported payments, led by Axonics, Inc. at 28.3% of the total. Reporting peaked in 2022 at $2,259 and has fallen 70.2% since, to $674 in 2025. Among women's health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$1K
- Astellas Pharma US Inc$571
- Sumitomo Pharma America, Inc.$440
- AbbVie$386
- Mayne Pharma Commercial LLC$284
- Myovant Sciences Inc.$156
- plus $2K from 26 others
What the payments were for
- Travel & lodging$87518%
- Food & beverage$3,70078%
- Education$1854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 11 | $1,348 |
| Astellas Pharma US Inc | 31 | $571 |
| Sumitomo Pharma America, Inc. | 27 | $440 |
| AbbVie | 21 | $386 |
| Mayne Pharma Commercial LLC | 10 | $284 |
| Myovant Sciences Inc. | 12 | $156 |
| Bayer | 9 | $151 |
| Pfizer | 9 | $141 |
| Organon | 7 | $124 |
| Urovant Sciences Inc | 8 | $123 |
| Aspira Women's Health Inc | 1 | $100 |
| Exeltis, USA Inc. | 6 | $98 |
| Shield Therapeutics Inc | 5 | $96 |
| Pacira Pharmaceuticals Incorporated | 3 | $82 |
| Hologic Sales And Service, LLC | 5 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Channel Medsystems, Inc. | 1 | $74 |
| Scynexis, Inc. | 4 | $69 |
| Lilly USA, LLC | 3 | $46 |
| Convatec Inc. | 2 | $43 |
| Evofem Biosciences, Inc. | 3 | $42 |
| Coopersurgical, Inc. | 1 | $33 |
| Kerecis Limited | 1 | $33 |
| Amgen | 2 | $27 |
| Agile Therapeutics, Inc. | 2 | $25 |
| Mylan Pharmaceuticals Inc. | 2 | $24 |
| Coloplast | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Therapeuticsmd, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$995
- NEXTSTELLIS$121
- Axonics r-SNM System$118
How this compares
$4,760 in reported general payments places this provider in the 90th percentile of 107 women's health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 20 | $8,722 |
| Estradiol | 58 | $1,489 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 16 | $591 |
| Estradiol (Twice Weekly)Estradiol | 13 | $569 |
| Solifenacin Succinate | 11 | $374 |
| Amitriptyline Hcl | 29 | $352 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $334 |
| Fluconazole | 28 | $182 |
| Tizanidine Hcl | 17 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $571 | $8,72220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 107 women's health providers in Alabama.
Other women's health in Birmingham
- Ashton TureaudBirmingham$26K
- Kathryn LyleBirmingham$7K
- Jessica MorrisonBirmingham$5K
- Katie FainBirmingham$3K
- Catherine VanceBirmingham$3K
- Brittany NguyenBirmingham$3K
- Anna LeaBirmingham$2K
- Madison HulkerBirmingham$2K
- Kelley CatronBirmingham$1K
- Cynthia PooreBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.